Related Experiment Video
Updated: Mar 12, 2026
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
Metastatic human epidermal growth factor receptor 2-positive breast cancer: Management, challenges, and future
Mohsin Soleja1, Mothaffar F Rimawi1
1Department of Medicine, Lester and Sue Smith Breast Center, and Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, Texas 77030.
Abstract:
HER2 is over-expressed or amplified in 15-20% of breast cancer. Significant progress has been made in the treatment of metastatic HER2+ breast cancer. This is largely due to successful targeting of the HER2 pathway. There are several approved agents in the metastatic setting. However, treatment resistance frequently develops and tumors eventually progress. In recent years, our understanding of mechanisms of resistance has evolved. It is generally accepted now that HER2-positive breast cancer is not one disease. New therapeutic strategies and a tailored approach to management are necessary to maximize patient outcomes and minimize toxicity.
Insights
HER2-positive breast cancer treatment has advanced, but resistance is common. Understanding resistance mechanisms reveals HER2-positive breast cancer is diverse, requiring personalized strategies for better outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- HER2 (Human Epidermal growth factor Receptor 2) is over-expressed in 15-20% of breast cancers.
- Targeting the HER2 pathway has led to significant progress in treating metastatic HER2-positive breast cancer.
- Approved HER2-targeted agents exist, but treatment resistance and tumor progression remain significant challenges.
Purpose of the Study:
- To review the evolving understanding of HER2-positive breast cancer treatment resistance mechanisms.
- To emphasize the heterogeneity of HER2-positive breast cancer.
- To advocate for novel therapeutic strategies and personalized management approaches.
Main Methods:
- Literature review of recent advancements in understanding HER2-positive breast cancer resistance.
- Analysis of current therapeutic strategies and their limitations.
- Synthesis of emerging concepts regarding tumor heterogeneity in HER2-positive disease.
Main Results:
- Mechanisms of treatment resistance in HER2-positive breast cancer are increasingly understood.
- HER2-positive breast cancer is recognized as a heterogeneous disease, not a single entity.
- Current treatment paradigms face limitations due to acquired resistance.
Conclusions:
- A deeper understanding of resistance mechanisms is crucial for improving patient outcomes.
- Personalized therapeutic strategies tailored to the heterogeneity of HER2-positive breast cancer are necessary.
- Future research should focus on developing novel agents and combination therapies to overcome resistance and minimize toxicity.
More Related Videos
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...